GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pliant Therapeutics PLRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.60

-4.02%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Pliant Therapeutics — daily PLRX Delayed
Market value
$36.5m
Last close × shares
Volume
933.4k
Shares, 20 Nov 2026

About Pliant Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Pliant Therapeutics is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PLRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $149.3m. At that date it held total assets of $225.2m and shareholders' equity of $181.2m.

In its own words

We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β). We have applied our deep understanding of integrin biology, along with our medicinal chemistry and translational medicine expertise to develop a proprietary drug discovery platform that we believe has broad applicability across multiple areas of disease.

Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in development for the treatment of solid tumors. In 2025, we announced positive data from a Phase 1 open-label dose-escalation trial of PLN-101095 as monotherapy and in combination with the immunotherapy pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. We also continue to explore the full potential of our drug discovery platform consisting of a proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.

Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗

More about Pliant Therapeutics →

Latest on Pliant Therapeutics

Our reporting

We have not reported on Pliant Therapeutics yet.

Next results

10 Mar 2027

Due on 10 Mar 2027. Analysts expect earnings of -0.37 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Pliant Therapeutics's ticker?

Pliant Therapeutics trades as PLRX on its US listing, under ISIN US7291391057.

What was Pliant Therapeutics's last closing price?

0.60 on 20 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.